- Home
- AGIO vs COMM Comparison
AGIO vs COMM Comparison
Compare AGIO & COMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- COMM
- Stock Information
- Founded
- AGIO 2007
- COMM 1976
- Country
- AGIO United States
- COMM United States
- Employees
- AGIO N/A
- COMM N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- COMM Radio And Television Broadcasting And Communications Equipment
- Sector
- AGIO Health Care
- COMM Technology
- Exchange
- AGIO Nasdaq
- COMM Nasdaq
- Market Cap
- AGIO 1.4B
- COMM 1.3B
- IPO Year
- AGIO 2013
- COMM 2013
- Fundamental
- Price
- AGIO $39.05
- COMM $7.53
- Analyst Decision
- AGIO Buy
- COMM Hold
- Analyst Count
- AGIO 6
- COMM 5
- Target Price
- AGIO $58.60
- COMM $4.88
- AVG Volume (30 Days)
- AGIO 602.7K
- COMM 5.8M
- Earning Date
- AGIO 07-31-2025
- COMM 08-07-2025
- Dividend Yield
- AGIO N/A
- COMM N/A
- EPS Growth
- AGIO N/A
- COMM N/A
- EPS
- AGIO 11.45
- COMM 3.42
- Revenue
- AGIO $37,035,000.00
- COMM $4,417,100,000.00
- Revenue This Year
- AGIO $22.30
- COMM $21.50
- Revenue Next Year
- AGIO $219.19
- COMM $8.30
- P/E Ratio
- AGIO $3.45
- COMM $2.21
- Revenue Growth
- AGIO 25.96
- COMM 16.19
- 52 Week Low
- AGIO $23.42
- COMM $1.32
- 52 Week High
- AGIO $62.58
- COMM $8.67
- Technical
- Relative Strength Index (RSI)
- AGIO 70.00
- COMM 55.72
- Support Level
- AGIO $34.60
- COMM $7.67
- Resistance Level
- AGIO $40.06
- COMM $8.67
- Average True Range (ATR)
- AGIO 1.49
- COMM 0.41
- MACD
- AGIO 0.43
- COMM -0.07
- Stochastic Oscillator
- AGIO 86.59
- COMM 55.29
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).